This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Understanding the latest R&D advances and clinical development trends in obesity management

Ticker(s): RHHBY, AMGN, AZN

Who's the expert?

Institution: Harvard Medical School

  • Medical Director, Obesity Clinic Program and Inpatient Diabetes Program & Associate Professor, Harvard Medical School.
  • Manages ~1,000 patients with diabetes.
  • Co-Investigator of two landmark studies: the national Diabetes Prevention Program and the Look AHEAD (Action for Health in Diabetes) Study.
  • Research interests include diabetes and obesity, metabolic syndrome and obesity and cardiovascular disease with a focus on understanding metabolic and cardiovascular benefits of lifestyle changes and weight loss. 

Interview Questions

What are the driving reasons behind the latest increased interest in GLP1+GPR dual agonists?

Added By: pharmaadvisor

What is the KOL's perception of Roche’s acquisition of Carmot Therapeutics and their pipeline for GLP-1/GIP Receptor Agonists? What is the potential of Carmot's pipeline to accelerate and extend weight loss? All three of Carmot’s assets have combination potential with Roche’s current products. How will this impact the perception of KOLs on potential future treatment, especially with CT-388?

Added By: pharmaadvisor

What is the KOL's opinion of Amgen's obesity management development pipeline programs, including their maridebart cafraglutide (AMG-133) asset, the once monthly GIPR antagonist, and GLP-1R agonist?

Added By: pharmaadvisor

 What are the trends and reasons companies are increasing investment into combination therapy for obesity?

Added By: pharmaadvisor

What do KOLs think about oral GLP-1 in terms of its value, positioning, and potential, given the current development work being done in obesity?

Added By: pharmaadvisor

What’s the next big thing in obesity after the current efficacy/GLP-1 focus? Are there any novel targets of interest?

Added By: pharmaadvisor

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.